Literature Highlights Old

Each week, the main highlight from a new Covid-19 research article will be summarized in an infographic. Please come back weekly for more infographic highlights covering diagnosis, risk factors, treatment, and more.

Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19

Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Therapeutic Versus Prophylactic Anticoagulation for Severe COVID-19: A Randomized Phase II Clinical Trial (HESACOVID)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Effects of COVID-19 on the Nervous System

COVID-19 Vaccine: A Comprehensive Status Report

Extrapulmonary Manifestations of COVID-19

Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis

Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report

Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-19: A Preliminary Report of a Phase 1/2, Single-Blind, Randomized Controlled Trial

An mRNA vaccine Aganist SARS-CoV-2 - Preliminary Report

Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial

Pilot Prospective Open, Single-arm Multicentre Study on Off-label Use of Tocilizumab in Patients With Severe COVID-19

Observational Study of Hydroxychlaraquine in Hospitalized Patients with COVID-19

Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital

Biomarkers Associated with COVID-19 Disease Progression

Remdesivir for the Treatment of COVID-19 - Preliminary Report

A Comparative Study on the Clinical Features of COVID-19 Pneumonia to Other Pneumonias

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Candidate drugs against SARS-CoV-2 and COVID-19

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Menu

Updates in the Treatment and Prevention of COVID-19​

Casirivimab and Imdevimab Approved in Japan for the Treatment of Mild-to-Moderate COVID-19

Japan’s Ministry of Health, Labour and Welfare (MHLW) has fully approved the combination of casirivimab and imdevimab to treat patients with mild-to-moderate COVID-19. This marks the first time a monoclonal-antibody cocktail has received full approval to treat COVID-19. This combination therapy is currently authorized for emergency use in more than 20 countries, including the United States, European Union, India, Switzerland, and Canada. The monoclonal antibody cocktail was approved in Japan after results from a phase 3 trial showed a 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients who received casirivimab and imdevimab. The MHLW also reviewed results from a phase 1 trial that analyzed the safety, tolerability, and pharmacokinetics of the combination therapy in Japanese subjects. Multiple analyses have shown that casirivimab and imdevimab retain potency against circulating variants of concern, including Delta (B.1.162.2, first seen in India), Gamma (P.1, first seen in Brazil), and Beta (B.1.351, first seen in South Africa).

Reference

https://newsroom.regeneron.com/news-releases/news-release-details/japan-becomes-first-country-approve-regeneron-antibody-cocktail